-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

Benzinga·10/06/2026 14:47:12
Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $12 to $14.